Pyxis Oncology (PYXS) Operating Leases (2020 - 2026)

Pyxis Oncology (PYXS) has reported Operating Leases for 6 consecutive years, with $16.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 10.23% year-over-year to $16.0 million in Q2 2026; TTM through Jun 2026 was $16.0 million, a 10.23% decrease from a year earlier, with the FY2025 full-year figure at $17.0 million, down 9.07% from the prior year.
• Operating Leases was $16.0 million for Q2 2026 at Pyxis Oncology, down from $17.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $20.7 million in Q2 2023 and troughed at $15.7 million in Q2 2022.
• A 5-year average of $18.4 million and a median of $18.8 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 32.2% in 2023 and fell 10.23% in 2026, its largest moves.
• Over 5 years, Operating Leases stood at $18.9 million in 2022, then grew by 6.23% to $20.1 million in 2023, then decreased by 7.21% to $18.6 million in 2024, then slipped by 9.07% to $17.0 million in 2025, then slipped by 5.6% to $16.0 million in 2026.
• The last three Operating Leases figures came in at $16.0 million (Q2 2026), $17.0 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.